Apollo Hospitals NCLT Approval Paves Way for Demerger

Introduction to the Restructuring

Apollo Hospitals Enterprise Limited (AHEL) has secured a pivotal approval from the National Company Law Tribunal (NCLT), Chennai Bench, for its proposed composite scheme of arrangement. The order, dated March 26, 2026, marks a significant milestone in the company's plan to restructure its business by demerging its omnichannel pharmacy and digital health operations into a new, separately listed entity named Apollo Healthtech Limited (AHTL). This strategic move is designed to unlock value, enhance operational focus, and create a formidable leader in India's rapidly growing digital health sector.

The Strategic Rationale

The primary objective behind this complex restructuring is to create a distinct and focused entity that combines Apollo's extensive pharmacy distribution network with its burgeoning digital health platform, Apollo 24|7. By consolidating these synergistic businesses, Apollo aims to achieve greater operational efficiency, streamline its supply chain, and accelerate growth. The creation of a separate listed company is also expected to attract dedicated investors and strategic partners focused on the health-tech space, providing AHTL with the agility and capital required to innovate and expand. Management believes this structure will improve administrative controls and transparency, ultimately benefiting shareholders of both the parent company and the new entity.

Anatomy of the Composite Scheme

The composite scheme of arrangement is a multi-step process involving several group companies. It is designed to consolidate the pharmacy and digital health assets under one umbrella.

1. Demerger from AHEL: The first step involves the demerger of AHEL's identified business undertaking, which includes its front-end omnichannel pharmacy distribution business and the Apollo 24|7 digital platform, into Apollo Healthtech Limited.
2. Amalgamation of Group Companies: Following the demerger, two other entities, Apollo Healthco Limited (AHL) and Keimed Private Limited, will be merged into AHTL. This consolidation brings together the digital platform, pharmacy distribution, and wholesale pharmaceutical operations.

This intricate arrangement will result in the creation of a powerful, integrated healthcare platform. The roles of the key entities are clarified below:

A Journey of Regulatory Approvals

Securing the NCLT's approval was the culmination of a meticulous regulatory process that began in 2025. The company systematically obtained clearances from various statutory bodies, demonstrating the soundness of its restructuring plan.

Each approval was a critical step, with stock exchanges like the NSE and BSE imposing conditions such as mandatory disclosures to shareholders and ensuring that new shares are issued only in dematerialized form.

Market Impact and Financial Outlook

The market has responded positively to the developments in Apollo's restructuring journey. Following the no-objection from the NSE in December 2025, the share price of Apollo Hospitals Enterprise Limited saw a notable increase, trading 1.8% higher at ₹7,205 on December 24, 2025. This reflects investor confidence in the value-unlocking potential of the scheme. The transaction values the combined pharmacy and digital health entity at an enterprise value of ₹22,481 crore. Furthermore, the newly formed Apollo Healthtech Limited has ambitious growth targets, aiming to achieve revenues of ₹25,000 crore by the fiscal year 2027.

Next Steps and Path to Listing

With the NCLT's order in hand, Apollo Hospitals is now proceeding to the final stages of the approval process. The company has scheduled meetings for its shareholders and creditors throughout May 2026 to secure their consent for the scheme. Once these approvals are obtained, and final regulatory formalities are completed, the path will be clear for the demerger and subsequent listing of Apollo Healthtech Limited on the stock exchanges. The initial timeline suggested a listing within 18 to 21 months from the scheme's announcement, positioning AHTL to become a publicly traded company in the near future.

Conclusion

The NCLT's approval is a decisive step forward in Apollo Hospitals' strategic vision to separate its core hospital business from its high-growth pharmacy and digital health operations. This restructuring is set to create a focused, agile, and powerful player in the Indian health-tech and pharmacy distribution landscape. As the company moves towards final shareholder approvals in May 2026, all eyes will be on the eventual listing of Apollo Healthtech Limited, a move that promises to unlock significant value for investors and reshape India's healthcare ecosystem.